Failed early
Atacicept: reduce relapses and new lesions in relapsing MS
relapsing MS · Other B-cell / plasma-cell targeting
Controlled phase 2 trials were negative.
- Trials
- 2
- Running now
- 1
- Controlled phase 2/3 trials
- 2
- People in controlled trials
- 587
Deciding trials (phase 2): 0 met, 1 did not.
Other linked trials: 1
Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.
Trials
Phase 2 · 2008 · Placebo-controlled · MSFT-NCT00642902
Mean numbers of gadolinium-enhancing T1 lesions per scan were similar in all groups (25 mg, 2·26, 0·97-5·27; 75 mg, 2·30, 1·08-4·92; 150 mg, 2·49, 1·18-5·27; placebo, 3·07, 1·40-6·77).
Read by software from the paper's abstractPhase 2 · 2008 · Placebo-controlled · MSFT-2007-003936-50
The deciding phase and counts come from the Trial Bank’s fixed rules.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- 2026-10-28Status changed from Being tested to Failed early
- 2026-10-27First listed as Being tested
Related hypotheses
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error